EHA 2022 | Drugs under investigation for the treatment of TA-TMA
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, gives an overview of the agents currently being evaluated in clinical trials for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), including eculizumab, narsoplimab, pegcetacoplan, and ravulizumab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Transcript (edited for clarity)
Yes, TA-TMA is a life threatening condition after allogeneic transplant. And we have many advances in the complement field. We know that there’s complement activation in TA-TMA, and we now know that complement inhibitors are effective and safe. We had the first results with eculizumab in scientifically driven studies then was narsoplimab, having a Phase II study with very encouraging results for our patients...
Yes, TA-TMA is a life threatening condition after allogeneic transplant. And we have many advances in the complement field. We know that there’s complement activation in TA-TMA, and we now know that complement inhibitors are effective and safe. We had the first results with eculizumab in scientifically driven studies then was narsoplimab, having a Phase II study with very encouraging results for our patients. And now we also have other drugs under study, like pegcetacoplan, a C3 inhibitor in TA-TMA and ravulizumab, a C5 inhibitor in TA-TMA, that are under clinical trials in our patients. Both drugs have been indicated for the treatment of PNH, which is the prototype disease of complement activation. So we now have like three drugs under development for TA-TMA, specifically, narsoplimab is under the compassionate use program. We are eager to have these drugs in clinical practice for our patients.
Read more...
